Document:

<PAGE>

                                                                       EXHIBIT I

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
(THE "SECURITIES ACT").  NO SALE OR TRANSFER OF THIS NOTE (OTHER THAN TO THE
ISSUER OF THIS NOTE) MAY BE MADE UNLESS EITHER (A) PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR (B) PURSUANT TO AN EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.

                               US ONCOLOGY, INC.

                       8.42% SENIOR SECURED NOTE DUE 2006

No. [_____]                                             November 24, 1999
 $[_______]                                             PPN: 90338W AA 1

  FOR VALUE RECEIVED, the undersigned, US Oncology, Inc. (herein called the
"Company"), a corporation organized and existing under the laws of the State of
Delaware, hereby promises to pay to [______________________], or registered
assigns, the principal sum of [_______________________________] DOLLARS on
November 24, 2006, with interest (computed on the basis of a 360-day year of
twelve 30-day months) (a) on the unpaid balance thereof at the rate of 8.42% per
annum from the date hereof, payable semiannually, on the 24th day of May and
November in each year, commencing with May 24, 2000, until the principal hereof
shall have become due and payable, and (b) to the extent permitted by law on any
overdue payment (including any overdue prepayment) of principal, any overdue
payment of interest and any overdue payment of any Make-Whole Amount (as defined
in the Note Purchase Agreements referred to below), payable semiannually as
aforesaid (or, at the option of the registered holder hereof, on demand), at a
rate per annum from time to time equal to the greater of (i) 10.42% or (ii) 2%
over the rate of interest publicly announced by Chase Bank, N.A. from time to
time in New York, New York as its "base" or "prime" rate.

  Payments of principal of, interest on and any Make-Whole Amount with respect
to this Note are to be made in lawful money of the United States of America at
Houston, Texas or at such other place as the Company shall have designated by
written notice to the holder of this Note as provided in the Note Purchase
Agreements referred to below.

  This Note is one of a series of Senior Secured Notes (herein called the
"Notes") issued pursuant to separate Note Purchase Agreements, dated as of
November 24, 1999 (as from time to time amended, the "Note Purchase
Agreements"), between the Company and the respective Purchasers named therein
and is entitled to the benefits thereof.  Each holder of this Note will be
deemed, by its acceptance hereof, (i) to have agreed to the confidentiality
provisions set forth in Section 21 of the Note Purchase Agreements and (ii) to
have made the representation set forth in Section 6.2 of the Note Purchase
Agreements.

  This Note is a registered Note and, as provided in, and subject to any
limitations set forth in, the Note Purchase Agreements, upon surrender of this
Note for registration of transfer, duly endorsed, or accompanied by a written
instrument of transfer duly executed, by the registered holder hereof or such
holder's attorney duly authorized in writing, a new Note for a like principal
amount
<PAGE>

will be issued to, and registered in the name of, the transferee.  Prior
to due presentment for registration of transfer, the Company may treat the
person in whose name this Note is registered as the owner hereof for the purpose
of receiving payment and for all other purposes, and the Company will not be
affected by any notice to the contrary.

  The Company will make required prepayments of principal on the dates and in
the amounts specified in the Note Purchase Agreements.  This Note is also
subject to optional prepayment, in whole or from time to time in part, at the
times and on the terms specified in the Note Purchase Agreements, but not
otherwise.

  If an Event of Default, as defined in the Note Purchase Agreements, occurs and
is continuing, the principal of this Note may be declared or otherwise become
due and payable in the manner, at the price (including any applicable Make-Whole
Amount) and with the effect provided in the Note Purchase Agreements.

  This Note and the obligations hereunder are secured by certain security
interests and guarantees pursuant to the Security Documents (as defined in the
Note Purchase Agreements) and the holder hereof is entitled to the benefits
thereof.

  Anything in this Note, the Note Purchase Agreements or the other Security
Documents to the contrary notwithstanding, the Company shall never be required
to pay interest on or with respect to this Note, the Note Purchase Agreements or
the other Security Documents at a rate in excess of the Highest Lawful Rate (as
defined below), and if the effective rate of interest that would otherwise be
payable on or with respect to this Note, the Note Purchase Agreements or the
other Security Documents would exceed the Highest Lawful Rate, or if the
registered holder of this Note shall receive anything of value that is deemed or
determined to constitute interest that would increase the effective rate of
interest payable on or with respect to this Note, the Note Purchase Agreements
or the other Security Documents to a rate in excess of the Highest Lawful Rate,
then (a) the amount of interest that would otherwise be payable on or with
respect to this Note, the Note Purchase Agreements or the other Security
Documents shall be reduced to the amount allowed at the Highest Lawful Rate
under applicable law, and (b) any unearned interest paid by the Company or any
interest paid by the Company in excess of the Highest Lawful Rate shall, at the
option of the registered holder of this Note, be either refunded to the Company
or credited on the principal of this Note or any other obligation outstanding
under or with respect to this Note, the Note Purchase Agreements or the other
Security Documents.  It is further agreed that, without limitation of the
foregoing, all calculations of the rate of interest contracted for, charged or
received by any registered holder of this Note, or under the Note Purchase
Agreements or the other Security Documents, that are made for the purpose of
determining whether such rate exceeds the Highest Lawful Rate, shall be made, to
the extent permitted by applicable law (now or, to the extent permitted by law,
hereafter enacted) governing the Highest Lawful Rate, by (i) characterizing any
non-principal payment as an expense, fee or premium rather than as interest, and
(ii) amortizing, prorating, allocating and spreading in equal parts during the
period of the full term of this Note (including the period of any renewal or
extension hereof), all interest at any time contracted for, charged or received
by such registered holder in connection herewith.  As used herein, the term
"Highest Lawful Rate" means the maximum non-usurious rate of interest permitted
from time to time to be contracted for, taken, charged or

                                      -2-
<PAGE>

received with respect to this Note, the Note Purchase Agreements or the other
Security Documents by the registered holder hereof, under applicable law in
effect with respect to this Note, the Note Purchase Agreements or the other
Security Documents.

  This Note shall be construed and enforced in accordance with the laws of the
state of Texas, excluding choice-of-law principles of the law of such state that
would require the application of the laws of a jurisdiction other than such
states.

                              US ONCOLOGY, INC.

                              By:
                                --------------------------------
                                  L. Fred Pounds
                                  Chief Financial Officer

                                      -3-<PAGE>

                                  US ONCOLOGY

                              EMPLOYMENT AGREEMENT

     This Agreement is made and entered into this  day of _______, , by and
between US ONCOLOGY, INC., a Delaware corporation (together with its
subsidiaries, hereinafter referred to as the "Company"), and __________
(hereinafter referred to as "Employee").  In consideration of the mutual terms,
conditions and covenants hereinafter set forth, the Company and
Employee agree to the following:

1.   TERM AND RENEWAL.

     Except as otherwise provided herein, the Company hereby agrees to employ
the Employee, and the Employee hereby agrees to remain in the employ of the
Company, for a three (3) year period commencing on the date of this Agreement.
Provided that this Agreement has not already been terminated, this Agreement
shall automatically renew for successive one-year terms, unless the Company
provides to the Employee written notice at least thirty (30) days prior to the
expiration of the initial or any renewal term that the Company is not renewing
this Agreement.

2.   POSITION AND DUTIES.

     The Employee, at the discretion of the Board of Directors, Chief Executive
Officer of the Company or his designee, in accordance with Company policy, shall
perform such duties and services as assigned.  The reporting relationship of the
Employee may from time to time be determined by the Board of Directors, Chief
Executive Officer or his designee and shall not be construed as a loss of
responsibility or a change in control.  Employee shall not have the authority to
enter into any contracts, agreements, undertakings or other arrangements on
behalf of the Company except to the extent that he is authorized to do so by the
Board of Directors, Chief Executive Officer of the Company or his designee.

     Employee shall, at all times, devote his full time and attention to the
business and affairs of the Company, and shall use his best efforts to perform
faithfully and efficiently such responsibilities.  The foregoing shall not be
construed as preventing the Employee from making passive investments in other
businesses or enterprises, provided, however, that:

          (i)  such investments would not require services on the part of the
               Employee which would in any way impair the performance of his
               duties under this Agreement;

          (ii) such investments are not in violation of any provision of Section
               5 or Section 6 of this Agreement; or

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 2

         (iii) such investments are not in violation of Company policies in
               effect from time to time.

     Employee shall not be required by the Company to be relocated out of the
Greater Houston metropolitan area, except for routine visits to the Company's
locations and except as may be necessary or desirable in the ordinary course of
the Company's business.

3.   COMPENSATION AND BENEFITS.

     The Company shall provide the following compensation to Employee for his
services under this Agreement:

     (a)  Base Salary.

     The Company shall pay Employee a base salary at an annual rate of $
___________

     (the "Base Salary").  The Base Salary shall be payable in equal semi-
monthly installments on the fifteenth and final days of each month during the
term of this Agreement or the standard payroll cycle in effect during this
Agreement.  The Base Salary may be reviewed and increased on an annual basis by
the Company's Board of Directors (or a committee thereof), as circumstances
dictate and in the sole discretion of the Company's Board of Directors (or a
committee thereof).

     (b)  Annual Bonus.

     The Employee shall be eligible for a bonus as determined by the Company's
Board of Directors (or a committee thereof).

     (c)  Expense Reimbursement.

     The Company shall reimburse Employee for all business-related expenses
incurred by Employee in conducting authorized business activities on behalf of
the Company; provided, however, that Employee must provide reasonably suitable
receipts and other records of the expenses to be reimbursed.

     (d)  Welfare Benefit Plans.

     In accordance with, and subject to, the terms of the applicable plan
documents, Employee shall be eligible to participate in such welfare benefit
plans of the Company as may be in effect from time to time.  The foregoing shall
not, in any respect, require the Company to implement, continue or amend any
plan.

     (e)  Vacation Holidays.

     Employee shall be eligible for such annual paid vacation, sick leave and
holidays as the Company may, in its discretion, provide for the employees of the
Company under the Company's policies and programs, it being agreed that the
foregoing shall not in any respect require the Company to continue or put into
effect any plan, practice, policy or program.  Employee shall have no right to
receive pay in lieu of vacation, sick leave or holidays, and upon the
termination of the Employee's employment pursuant to this Agreement, all
unearned vacation, sick leave or holidays shall be lost.

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 3

     (f)  The compensation paid pursuant to Sections 3(a) and 3(b) of this
Agreement as referred to herein shall be subject to any and all applicable
payroll and withholding deductions required by the law of any jurisdiction,
state or federal, with taxing authority with respect thereto.

4.  TERMINATION.

     (a)  Termination Events.

     This Agreement, and the employment relationship between Employee and the
Company, shall terminate upon the occurrence of any of the following:

          (i)   the death of Employee;

          (ii)  the disability, as defined and determined by the Company's Long
                Term Disability carrier, of Employee for a continuous period of
                at least six (6) months;

          (iii) the Company providing Employee with written notice that it is
                genuinely dissatisfied with his performance and is therefore
                terminating his employment;

          (iv)  the expiration of the thirtieth (30th) day after the Company
                provides Employee with written notice that it is terminating his
                employment without cause, or for any reason that does not
                constitute genuine dissatisfaction with his performance;

          (v)   the expiration of the thirtieth (30th) day after Employee
                provides the Company with written notice that he is resigning
                his employment.

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 4

          (vi)  the expiration of the stated term of this Agreement, as it may
                from time to time be extended.

          (vii) the Company may by action of the Board of Directors, Chief
                Executive Officer or his designee terminate Employee's
                employment under this Agreement for cause without any prior
                notice, upon the occurrence of any of the following events:

                (a)  the conviction of Employee, whether or not appeal be taken,
                     of any misdemeanor or felony crime involving personal
                     dishonesty, moral turpitude or willfully violent conduct;

                (b)  any embezzlement or wrongful diversion of funds of the
                     Company or any affiliate of the Company;

                (c)  gross business misconduct by Employee;

                (d)  gross malfeasance by Employee in the conduct of his duties;

                (e)  breach of Section 5 or Section 6 of this Agreement; or

                (f)  any other breach of any of the terms of this Agreement and
                     such breach has not been corrected after the Company has
                     given Employee reasonable notice thereof and a reasonable
                     opportunity to correct any such breach.

          (viii) the Employee providing the Company with written notice that the
                 Company has breached the last paragraph of Section 2 hereof.

     (b)  Effect of Termination and Severance Benefits.

     If this Agreement is terminated under Section 4(a)(i), Section 4(a)(ii),
Section 4(a)(iii), Section 4(a)(iv) or Section 4(a)(viii), then Employee shall
be entitled to termination pay.  Employee shall continue to receive his Base
Salary from the date of termination for a period equal to the greater of one (1)
year or the remaining term of this Agreement.  In addition, the Employee will be
eligible to receive COBRA benefits.  The Company shall make such severance
payments on a monthly basis, equal to the annual base salary then in effect
divided by twelve (12).  The monthly severance payments shall be made by the end
of the first payroll cycle currently in effect.

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 5

     If this Agreement is terminated under Section 4(a)(v), Section 4(a)(vi) or
Section 4(a)(vii), then Employee shall be entitled to no additional compensation
following the date of termination.

     If Employee is fifty (50) or more years of age at the time his
employment terminates under Section 4(a)(i), Section 4(a)(ii), Section
4(a)(iii), Section 4(a)(iv) or Section 4(a)(viii), and Employee has worked for
the Company for five (5) or more years prior to his termination, then Employee
and eligible dependents at the time of terminating event shall be permitted, in
addition to any other benefits, to participate in the Company's health benefit
plan, at Employee's expense, until age 65.  This provision is not applicable,
however, if the provisions of the Company's health benefit plan in effect during
coverage period up to age 65 terminates.  In this event, the Company will make
available an equivalent individual policy of comparative coverage, payable by
Employee up to the Company's then current group rate.  In the event of Medicare
eligibility, the Company's obligation for providing insurance coverage ceases.

     (c) Survival of Provisions Following Termination.

     Notwithstanding any termination of this Agreement, Sections 3, 4, 5, 6, 7,
8, 9 and 10 of this Agreement, and the rights and obligations created therein,
shall survive without limitation.

5.   CONFIDENTIALITY.

     (a)  Confidential and Proprietary Information.

     The Company's business profitability and good will are directly dependent
upon the confidential development, implementation and use of various marketing
and purchasing strategies, management and operating techniques, designs and
systems and other matters of a similar proprietary nature.  Such activities
necessarily include, without limitation, reviewing financial data, presentation
or sales materials, materials regarding the Company's affiliated physician
groups, materials regarding the Company's products and lists or other
compilations of information concerning aspects of the Company's business and
existing and prospective clients, and the business, operations and affairs of
the Company's existing and prospective clients.  All such information is
proprietary in nature, and the Company strives to keep such information
confidential (hereinafter collectively referred to as the Company's
"Confidential and Proprietary Information").

     To enhance Employee's work performance and abilities, the Company has
agreed to and will provide Employee with access to, and the right to use its
Confidential and Proprietary Information.  Employee acknowledges that such
information is, and must be treated as, confidential.  Employee further
acknowledges that access to, and

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 6

knowledge of, the Company's Confidential and Proprietary Information will give
him a competitive advantage in any future endeavors.

     (b)  Confidentiality Maintained.

     Employee is or will be employed in a position which is directly involved in
the development and conduct of the Company's business, and in such capacity
Employee will be provided access to and will gain knowledge of the Company's
Confidential and Proprietary Information.  Employee shall, both during and after
his employment by the Company, preserve, protect and hold in strictest
confidence the Company's Confidential and Proprietary Information.  Employee
will at all times, during and after the term of this Agreement, strictly observe
and comply with the terms of any confidentiality or similar agreements between
the Company and its clients.

     (c)  No Use of Information.

     Employee shall not, either during or after his employment with the Company,
use for himself or disclose to or use for any other persons, directly or
indirectly, any of the Company's Confidential and Proprietary Information,
except in carrying out his duties and responsibilities as an employee of the
Company or as such disclosure or use is expressly authorized by the Company in
writing.

     (d)  Non-Removal of Records.

     All Confidential and Proprietary Information and all files, reports,
computer discs, tapes, cards or other computer records, materials, designs,
records, documents, notes, memoranda, specifications, equipment and other items,
and any originals or copies thereof, relating to the business of the Company
which the Employee is either provided, prepares himself, uses, or otherwise
acquires during his employment with the Company, are and shall remain the sole
and exclusive property of the Company, and no such items (to the extent they
exist or are recorded in any tangible form) shall be removed from the Company's
premises without the prior consent of the Company, and all such items shall be
immediately returned to the Company upon termination of the Employee's
employment with the Company.

     (e)  Exceptions.

          (i)  The restrictions contained in this Section 5 shall not apply to
               any information that is or becomes generally available to and
               known by the public (other than as a result of unpermitted
               disclosure directly or indirectly by Employee or his affiliates,
               advisors or representatives).

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 7

          (ii) It shall not be a breach or violation of Employee's covenants
               under Section 5 if a disclosure is made pursuant to a court
               order, a valid administrative subpoena or a lawful request for
               information by an administrative or regulatory agency. Employee
               shall give the Company prompt notice of any such court order,
               subpoena or request for information.

6.   NON-COMPETITION AND NON-SOLICITATION.

     (a)  Consideration Acknowledged.

     Employee acknowledges that his employment with the Company has been, and
will continue to be, special, unique and of an extraordinary character and that,
in connection with such employment, he has acquired, acquires, and will continue
to acquire, special skills and training.  Employee further acknowledges that the
covenants contained in this Section 6 are an essential part of his engagement by
the Company and that, but for his agreement to comply with such covenants, the
Company would not have entered into this Agreement.  Finally, Employee
acknowledges that he has gained access to and use of the Company's Confidential
and Proprietary Information because of his covenants contained in this Section
6, and that he would be competitively advantaged against the Company because of
his knowledge of such Confidential and Proprietary Information.

     (b)  Employee Covenant.

     Employee covenants, and agrees, that he shall not, during the Employment
Period and for a period of one (1) year after the termination of his employment
with the Company:

          (i)  directly or indirectly, either as principal, agent, independent
               contractor, consultant, director, officer, employee, employer,
               advisor, stockholder, partner or in any other individual or
               representative capacity whatsoever, either for his own benefit or
               for the benefit of any other person or entity either (a) hire,
               attempt to hire, contact or solicit with respect to hiring any
               employee of the Company or (b) induce or otherwise counsel,
               advise or encourage any employee of the Company to leave the
               employment of the Company; or

          (ii) directly or indirectly, either as principal, agent, independent
               contractor, consultant, director, officer, employee, employer,
               advisor, stockholder, partner or in any other individual or
               representative capacity whatsoever, either for his own

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 8

                 benefit or for the benefit of any other person or entity,
                 solicit, divert or take away any existing or prospective
                 customers, clients, affiliated physician groups or affiliated
                 physicians of the Company, who were such during his employment
                 with the Company; or

          (iii)  act or serve, directly or indirectly, as principal, agent,
                 independent contractor, consultant, director, officer,
                 employee, employer or advisor or in any other position or
                 capacity with or for, or acquire a direct or indirect ownership
                 interest in or otherwise conduct (whether as stockholder,
                 partner, investor, joint venturer or as owner of any other type
                 of interest) any business, undertaking or entity that conducts
                 a business similar to the Business (as hereinafter defined) or
                 provides or sells a service which is the same or substantially
                 similar to, or otherwise competitive with, the services
                 provided by the Business within the United States of America.
                 "Business" shall mean (i) management and administration of the
                 non-medical aspects of oncology and diagnostic radiology
                 practices, (ii) operation and management of a clinical research
                 or site management organization focusing on oncology or
                 diagnostic radiology, (iii) any Internet or technology based
                 applications focusing on oncology or diagnostic radiology or
                 (iv) any business or undertaking substantially similar to any
                 of the foregoing.

     (c)  Anti-Disparagement.

     Employee shall not, either during or after the termination of Employee's
employment with the Company, make any public or private remarks or comments that
are intended, or could reasonably be construed as, disparaging of the Company,
its directors, officers, products, business or services.

     (d)  Limitation on Scope.

     Should any portion of this Section 6 be deemed unenforceable because of the
scope, duration or territory encompassed by the undertakings of the Employee
hereunder, and only in such event, then the parties consent and agree to such
limitation on scope, duration or territory as may be finally adjudicated as
enforceable by a court of competent jurisdiction after the exhaustion of all
appeals.

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 9

7.   EFFECT OF CHANGE OF CONTROL.

     For purposes of this Agreement, a "Change of Control" is defined as (i) the
transfer of beneficial ownership of a majority of the outstanding shares of US
Oncology stock to any person or entity (including a "group" as such term is used
in Section 13(d)(3) of the Securities Exchange Act of 1934); (ii) the
stockholders of the Company prior to any merger, consolidation or other
transaction do not continue to own at least fifty percent (50%) of the surviving
entity following such merger, consolidation or other transaction; (iii) the
Company sells, leases or exchanges all or substantially all if its assets to any
other person or entity (other than a wholly owned subsidiary of the Company);
(iv) the Company is materially or completely liquidated; or (v) during any
consecutive two-year period, individuals who constituted the Board of Directors
of the Company  (together with any new directors whose election by the Board of
Directors or whose nomination for election by the stockholders of the Company
was approved by a vote of at least three quarters of the directors still in
office who were either directors at the beginning of such period or whose
election or nomination  for election was previously so approved) cease for any
reason to constitute a majority of the Board of Directors then in office .
Notwithstanding anything contained herein to the contrary, a "Change of Control"
shall not be deemed to have occurred in the event of a tender offer, leveraged
buyout, leveraged recapitalization or similar transaction in which one or more
then executive officers of the Company participates directly or indirectly as an
investor or participant in such transaction.  If a Change of Control occurs,
then the following provisions become applicable and prevail over any
inconsistent provisions found in this Agreement:

     (a) The term of this Agreement shall automatically extend to a period of
three (3) years commencing on the date of the Change of Control, and may, upon
the expiration of that three (3) year term, be renewed for successive one (1)
year terms as provided for in Section 1 of this Agreement;

     Employee may, at any time within six (6) months (consideration period) of
the date of the Change of Control, terminate his employment for any reason, or
no reason at all, by providing written notice of his resignation to the Company.
Upon submitting such a resignation within six (6) months of the date of the
Change of Control, Employee shall, for a period of twelve (12) months from the
date of termination, continue to receive his Base Salary and be eligible to
participate in the Company's COBRA benefit plan.  The Company shall make such
severance payments on a monthly basis, equal to the annual base salary then in
effect divided by twelve (12).  The monthly severance payments shall be make by
the end of the first payroll cycle currently in effect.

     (b) If Employee does not submit such a resignation within six (6) months of
the date of the Change of Control, Employee termination rights, and eligibility
for any severance benefits, revert to only those provided for in Section 4 of
this Agreement.

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 10

8.   REMEDIES AND DISPUTE RESOLUTION.

     With respect to each and every breach or violation or threatened breach or
violation by Employee of Section 5 or Section 6 of this Agreement, the Company
may, in addition to all other remedies available to it, file a lawsuit or
otherwise apply to any court of competent Jurisdiction for entry of an immediate
order enjoining or restraining Employee from engaging in any such breach or
violation or threatened breach or violation by Employee.

     With the exception of the Company's right to seek injunctive relief in a
judicial forum for any breach or violation or threatened breach or violation by
employee of Section 5 or Section 6 of this Agreement, all disputes between
Employee and the Company that arise out of concern, or are based, in whole or in
part, upon any provision of this Agreement shall be resolved through binding
arbitration conducted under the Employment Arbitration Procedures of the
American Arbitration Association.  The parties shall bear their own costs in any
such arbitration proceeding; provided, however, that the Company shall reimburse
the Employee for the Employee's legal costs, including attorneys' fees, incurred
in such arbitration proceeding if the Employee substantially prevails in such
arbitration proceeding.

9.   SEVERABILITY.

     The provisions of this Agreement are severable, and any judicial
determination that one or more of such provisions, or any portion thereof, is
invalid or unenforceable shall not affect the validity or enforceability of any
other provisions, or portion thereof, but rather shall cause this Agreement to
first be construed in all respects as if such invalid or unenforceable
provisions, or portions thereof, were modified to terms which are valid and
enforceable and provide the greatest protection to the Company's business and
interests; provided, however, that if necessary to render this Agreement
enforceable, it shall be construed as if such invalid or unenforceable
provisions, or portions thereof, were omitted.

10.   SUCCESSORS.

     (A)  Employee.

     This Agreement is personal and without the prior written consent of the
Company shall not be assignable by the Employee otherwise than by will or the
laws of descent and distribution.

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 11

     (B)  Company.

     This Agreement is personal and without the prior written consent of the
Employee shall not be assignable by the Company.  This Agreement shall inure to
the benefit of and be binding upon the Company and its successors and assigns.

11.   MISCELLANEOUS.

     (a)  Governing Law; Captions; Amendment.

     This Agreement shall be governed by and construed in accordance with the
laws of the State of Texas, without reference to principles of conflict of laws.
The captions of this Agreement are not part of the provisions hereof and shall
have no force or effect.  This Agreement may not be amended or modified
otherwise than by a written agreement executed by the parties hereto or their
respective successors and legal representatives.

     (b)  Notices.

     All notices and other communications hereunder shall be in writing and
shall be given by hand delivery to the other party or by registered or certified
mail, return receipt requested, postage prepaid addressed as follows:

     If to the Employee:

           ---------------------

     If to the Company:

          c/o Chief Executive Officer
          US Oncology, Inc.
          16825 Northchase Drive, #1300
          Houston, Texas  77060

or to such other address as any party shall have furnished to the other in
writing in accordance herewith.  Notice and communications shall be effective
when actually delivered to the addressee or when delivered to the address
specified in accordance with the terms of this Agreement.

<PAGE>

US Oncology                                                        Confidential
Employee Agreement                                                 ------------
Page 12

     (c)  Entire Agreement.

     This Agreement contains the entire understanding of the Company and the
Employee with respect to the subject matter hereof and supersedes and completely
replaces any earlier agreement, written or oral, with regard thereto.

     IN WITNESS WHEREOF, the Employee has hereunto set his hand and the Company
has caused this Agreement to be executed in its name and on its behalf, all as
of the day and year first above written.

                                    EMPLOYEE

                                    -------------------------------

                                    US Oncology, Inc.

                                    By:----------------------------
                                         R. Allen Pittman
                                         Chief Administrative Officer &
                                         Vice President of Corporate Services
                                         US Oncology, Inc.

                                    For: R. Dale Ross
                                         Chief Executive Officer
                                         US Oncology, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]